Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report
详细信息 查看全文
- 作者：Ana Vidovic (6)
Valentina Arsic-Arsenijevic (7)
Dragica Tomin (6)
Irena Djunic (6)
Radoslav Jakovic (8)
Zlatibor Loncar (9)
Aleksandra Barac (7) - 关键词：Acute myeloblastic leukemia ; Early laboratory diagnosis ; Invasive pulmonary mucormycosis
- 刊名：Journal of Medical Case Reports
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：7
- 期：1
- 全文大小：349 KB
- 参考文献：1. Chayakulkeeree M, Ghannoum MA, Perfect JR: Zygomycosis: the re-emerging fungal infection. / Eur J Microbiol Infect Dis 2006, 25:215-29. CrossRef
2. D?hner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, L?wenberg B, Bloomfield CD, European LeukemiaNet: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. / Blood 2010, 115:454-74. CrossRef
3. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP: Epidemiology and clinical manifestations of mucormycosis . / Clin Infect Dis 2012,54(Suppl 1):23-4. CrossRef
4. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL: The epidemiologic features of invasive mycotic infection in the San Francisco bay area 1992-993: results of a population-based laboratory active surveillance. / Clin Infect Dis 1998, 27:1138-147. CrossRef
5. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP: Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. / Clin Infect Dis 2005, 41:60-6. CrossRef
6. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-003). / Haematologica 2006, 91:986-89.
7. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. / Clin Infect Dis 2005, 41:634-53. CrossRef
8. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP: Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). / Clin Infect Dis 2012,54(Suppl 1):55-0. CrossRef
9. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus -active antifungal therapy: a case–control observational study of 27 recent cases. / J Infect Dis 2005, 191:1350-360. CrossRef
10. Shirazi F, Kontoyaiannis DP: Mitochondrial respiratory pathways inhibition in Rhizopus oryzae potentiates activity of posaconazole and itraconazole via apoptosis. / Plos ONE 2013,8(5):1-1. CrossRef
11. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF: Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. / Haematologica 2005,90(Suppl 12):ECR39.
12. Rickerts V, Atta J, Herrmann S, Jacobi V, Lambrecht E, Bialek R, Just-Nübling G: Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. / Mycoses 2006,49(Suppl 1):27-0. CrossRef
13. Katragkou A, Roilides E: Immunotherapy of infections caused by rare filamentous fungi. / Clin Microbiol Infect 2012,18(2):134-39. CrossRef
14. John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. / Clin Microbiol Infect 2005, 11:515-17. CrossRef
15. Reed C, Ibrahim A, Edwards JE, Walot I, Spellberg B: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. / Antimicrob Agents Chemother 2006, 50:3968-969. CrossRef - 作者单位：Ana Vidovic (6)
Valentina Arsic-Arsenijevic (7)
Dragica Tomin (6)
Irena Djunic (6)
Radoslav Jakovic (8)
Zlatibor Loncar (9)
Aleksandra Barac (7)
6. Clinic of Hematology, Clinical Center of Serbia, Dr KosteTodorovi?a 2, Belgrade, Serbia
7. Institute of Microbiology and Immunology, Faculty of Medicine University of Belgrade, Dr Subotica 1, Belgrade, Serbia
8. Institute of Pulmonary diseases, Tuberculoses and Thorax Surgery, Clinical Center of Serbia, Dr KosteTodorovi?a 26, Belgrade, Serbia
9. Clinic for Emergency Surgery, Emergency Center of Serbia, Pasterova 2, Belgrade, Serbia - ISSN：1752-1947
文摘
Introduction Invasive mucormycosis (zygomycosis) is the third most frequent fungal infection in patients with hematologic malignancies. It often results in a fatal outcome mainly due to the difficulty of early diagnosis and its resistance to antimycotics. Case presentation A 52-year-old Caucasian man was diagnosed with acute myeloblastic leukemia. Following the induction chemotherapy he developed febrile neutropenia. Meropenem (3×1000mg/day) was introduced empirically. A chest computed tomography showed soft-tissue consolidation change in his right upper lobe. A bronchoscopy was performed and the histology indicated invasive pulmonary aspergillosis based on fungal hypha detection. Also, high risk patients are routinely screened for invasive fungal infections using commercially available serological enzyme-linked immunosorbent assay tests: galactomannan and mannan (Bio-Rad, France), as well as anti-Aspergillus immunoglobulin G and/or immunoglobulin M and anti-Candida?immunoglobulin G and/or immunoglobulin M antibodies (Virion-Serion, Germany). Galactomannan showed low positivity and voriconazole therapy (2×400mg/first day; 2×300mg/following days) was implemented. The patient became afebrile and a partial remission of disease was established. After 2 months, the patient developed a fever and a chest multi-slice computed tomography showed soft-tissue mass compressing his upper right bronchus. Voriconazole (2×400mg/first day; 2×300mg/following days) was reintroduced and bronchoscopy was repeated. Histologic examination of the new specimen was done, as well as a revision of the earlier samples in the reference laboratory and the diagnosis was switched to invasive pulmonary mucormycosis. The treatment was changed to amphotericin B colloidal dispersion (1×400mg/day). The complete remission of acute myeloblastic leukemia was verified after 2 months. During his immunerestitution, a high positivity of the anti-Aspergillus?immunoglobulin M antibodies was found in a single serum sample and pulmonary radiography was unchanged. A lobectomy of his right upper pulmonary lobe was done and the mycology culture of the lung tissue sample revealed Rhizopus oryzae. He remained in complete remission for more than 1 year. Conclusions Invasive mucormycosis was successfully treated with amphotericin B, surgery and secondary itraconazole prophylaxis. As a rare disease invasive mucormycosis is not well understood by the medical community and therefore an improvement of education about prevention, diagnosis and treatment of invasive mucormycosis is necessary.